Both target GIP and GLP-1 receptors. Both show over 20% body weight loss. But these are different molecules with different histories, and picking between them is less obvious than the headlines suggest.

I've followed both compounds since their earliest publications. Tirzepatide is already the benchmark. Mazdutide is closing the gap fast. Here's what we actually know as of early 2026.

The mechanism: why two receptors beat one

Semaglutide works through the GLP-1 receptor alone. Powerful stuff: slows gastric emptying, boosts insulin secretion, suppresses appetite via the hypothalamus. But GLP-1 is only part of the equation.

GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone that spent decades in the shadows. Turns out, activating GIP receptors drives thermogenesis in brown adipose tissue and improves lipid metabolism through pathways GLP-1 can't reach on its own.

[[Tirzepatide|10]] and [[Mazdutide|13]] both engage this dual system. They just do it differently.

Tirzepatide: a decade of data

Tirzepatide is a 39-amino-acid synthetic peptide. It binds the GIP receptor with affinity comparable to native GIP, and the GLP-1 receptor at roughly 5-fold lower affinity than native GLP-1. That imbalance is intentional — it delivers strong metabolic effects without overstimulating the GLP-1 pathway.

The SURPASS program (type 2 diabetes) enrolled over 20,000 participants. At the maximum 15mg dose, HbA1c dropped 2.07% versus 1.86% with semaglutide 1mg in SURPASS-2. Tirzepatide won the head-to-head on glycemic control.

But the real attention-grabber was weight loss. SURMOUNT-1 (2022): 2,539 participants without diabetes. Results over 72 weeks:

5mg — minus 15.0% body weight. 10mg — minus 19.5%. 15mg — minus 20.9%. Placebo — minus 3.1%.

Twenty percent body weight gone in 18 months. For obesity pharmacotherapy, those numbers were unprecedented. SURMOUNT-2 confirmed the effect in patients with diabetes: minus 14.7% at 15mg.

When you buy tirzepatide, you're getting access to a compound backed by one of the largest clinical trial programs in metabolic therapy history.

Mazdutide: the fast-rising contender from China

Mazdutide (IBI362) was developed by Innovent Biologics. Also a GIP/GLP-1 dual agonist, but a different molecule with distinct pharmacokinetics.

The key difference: mazdutide is built on a modified GLP-1 analog with an attached GIP-active fragment and an IgG4 Fc domain for extended half-life. That gives it a half-life of around 9 days, supporting once-weekly dosing.

The GLORY program is the main data source. GLORY-1 (phase III, 2024): 610 participants with obesity in China. Over 48 weeks, weight loss reached up to 17.4% at the 9mg dose.

GLORY-2 (type 2 diabetes): HbA1c reduction up to 1.62% with 10.2% weight loss on 6mg. The numbers are strong, though no direct comparison with tirzepatide exists within a single trial.

If you're looking to buy mazdutide for research purposes, keep in mind that the molecule is younger and safety data is still accumulating — but the early results are genuinely impressive.

Head-to-head: what the numbers say

One caveat upfront: no direct head-to-head trial between tirzepatide and mazdutide has been conducted. This comparison draws from separate programs with different populations.

Weight loss. Tirzepatide 15mg: 20.9% over 72 weeks (SURMOUNT-1). Mazdutide 9mg: 17.4% over 48 weeks (GLORY-1). If you extrapolate mazdutide's trajectory to 72 weeks, the gap may narrow. But for now, tirzepatide leads on absolute numbers.

Glycemic control. Tirzepatide showed a 2.07% HbA1c reduction (SURPASS-2, 15mg). Mazdutide — 1.62% (GLORY-2, 6mg). Different doses, different populations, but the trend favors tirzepatide.

Speed of effect. Both programs show meaningful weight loss kicking in by weeks 12-16. Plateau hits somewhere between weeks 40 and 60. No major difference here.

Side effects

The side effect profile for both is predictably gastrointestinal. Nausea, diarrhea, appetite suppression — standard incretin territory.

Tirzepatide (SURMOUNT-1): nausea 24-33% (dose-dependent), diarrhea 18-23%, constipation 11-17%. Most episodes were mild to moderate, peaking in the first 4-8 weeks and declining after.

Mazdutide (GLORY-1): nausea 26%, diarrhea 13%, vomiting 10%. Similar pattern, though baseline GI complaint rates can differ in a Chinese population cohort.

Both use gradual dose titration to minimize nausea. Tirzepatide starts at 2.5mg, increasing every 4 weeks. Mazdutide follows a similar low-start protocol.

What else is on the horizon

Tirzepatide already has FDA approval for obesity (Zepbound) and diabetes (Mounjaro). Mazdutide has filed for approval in China. Globally, mazdutide is still in phase III.

Meanwhile, the next generation is already here: [[Retatrutide|11]] — a triple agonist hitting GIP, GLP-1, and glucagon receptors. Phase II data showed weight loss up to 24.2% over 48 weeks. That puts it in bariatric surgery territory without the scalpel.

For those looking in a different direction, there's [[Cagrilintide|12]] — an amylin analog working through a separate satiety pathway. Its combination with semaglutide (CagriSema) showed minus 22.7% in phase III.

Who should consider what

If you want the most thoroughly studied dual agonist with the largest evidence base — [[Tirzepatide|10]] is it. Tirzepatide has been tested on tens of thousands of patients, approved in multiple jurisdictions, and its safety profile is documented over 2+ years.

If mazdutide interests you as a research peptide or for populations where it completed its main trials — [[Mazdutide|13]] delivers strong results and offers a different pharmacokinetic profile worth studying.

Want to order tirzepatide online or figure out the right dosing? Get in touch — we'll help match a protocol to your goals.

One more molecule worth considering in the metabolic health context is [[NAD+|14]]. NAD+ operates through an entirely different pathway (sirtuins and mitochondria), but its potential combination with incretins is actively discussed in clinical circles.

This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.